Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631128 | 0.88 | TAAR1 (0.51) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL13151306 | 0.86 | TOP2A (0.47) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL4751007 | 0.85 | TOP2A (0.46) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL18377688 | 0.80 | ALDH1A1 (0.54) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL30946374 | 0.80 | TOP2A (0.52) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL31285046 | 0.78 | TOP2A (0.48) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL31284789 | 0.78 | TOP2A (0.48) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL13151274 | 0.77 | NPBWR1 (0.46) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL18367564 | 0.76 | TOP2A (0.49) | TOP2ANPBWR1ALOX15ALDH1A1KDM4E | |
| SCHEMBL10150643 | 0.75 | LMNA (0.47) | NPBWR1ALOX15ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008062296-A2 | NOP RECEPTOR AGONISTS FOR THE TREATMENT OF L-DOPA INDUCED DYSKINESIAS | UNIVERSITA' DEGLI STUDI DI FERRARA (IT) | 2008-05-29 | — | — | WO | claimed |
| EP-3442526-B1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3442526-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Melinta Subsidiary Corp. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| WO-2017200979-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| CN-107205989-A | The method for the treatment of, prevention or reduction skin infection risk | 梅琳塔治疗公司 | 2017-09-26 | — | — | CN | disclosed |
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| EP-1904489-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | Rib-X Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006133397-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234615-A1 | Process for the synthesis of triazoles | PROKR1, SI, IL33 | TOP2A 394/4885NPBWR1 3120/4885ALOX15 426/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | TOP2A 82/4885NPBWR1 2615/4885ALOX15 1153/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | TOP2A 535/4885NPBWR1 2321/4885ALOX15 173/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | TOP2A 535/4885NPBWR1 2321/4885ALOX15 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.